Published in the journal Medicine, a single-center retrospective cohort study found that a greater periovulatory decrease in estradiol continued to show a modest link to reduced chances of clinical pregnancy, even though the availability of top-quality embryos remained comparable.
The study investigated whether the proportional shift in serum estradiol levels from the trigger point to the retrieval stage relates to clinical pregnancy outcomes within fresh gonadotropin-releasing hormone antagonist intracytoplasmic sperm injection cycles. The analysis included 849 cycles from 727 patients.
Cycles were classified into three distinct categories based on their hormone trajectory. Group A included 272 cycles with a decline of 45% or greater. Group B contained 279 cycles experiencing a decline of greater than 30% to less than 45%. Group C encompassed 298 cycles showing a decline of 30% or less, or an increase.
Clinical pregnancy cycles show smaller estradiol decline
Of the total 849 cycles evaluated, 391 tests returned positive, representing 46.1% of the cohort. A total of 340 cycles, or 40.0%, resulted in clinical pregnancy featuring fetal cardiac activity.
Cycles that achieved clinical pregnancy showed a smaller estradiol decline than those that did not, with a median drop of -34.7% compared to -39.6%. This difference was statistically significant with a p-value of less than 0.001. Meanwhile, the absolute estradiol difference showed no significant variation between groups, registering at p = 0.878.
Clinical pregnancy rates differed across the categorized groups at 30.5%, 45.5%, and 43.6%. These variations occurred despite comparable fertilization rates, top-quality embryo availability, and identical numbers of embryos transferred across the patient cohorts.
Adjusted odds ratio confirms estradiol change association
After multivariable adjustment, proportional estradiol change remained associated with clinical pregnancy. The adjusted odds ratio stood at 1.090 per 10-percentage-point increase, with a 95% confidence interval of 1.005 to 1.183 and a p-value of 0.038. Generalized estimating equations yielded similar results for repeated cycles within patients, while spontaneous abortion rates remained comparable among all groups.
These findings build upon earlier investigations into antagonist-assisted reproductive technology and trigger timing protocols. A subsequent study published in the Journal of Assisted Reproduction and Genetics examined the magnitude of post-retrieval estradiol decline in high responders undergoing similar protocols.
Additional systematic reviews, such as work published in the Cochrane Database of Systematic Reviews, previously evaluated gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for oocyte triggering. Further evaluation of dual trigger protocols appeared in research published in BMC Pregnancy and Childbirth on July 22, 2022.
Questions About Hormone Decline and IVF Cycles
What was the primary outcome measured in the cohort study?
The primary outcome was clinical pregnancy confirmed by the presence of fetal cardiac activity. Researchers tracked this across 849 cycles to evaluate how hormone shifts impact success rates.
How were the study cycles categorized based on hormone levels?
Cycles were divided into Group A with a decline of 45% or more (272 cycles), Group B with a decline between 30% and 45% (279 cycles), and Group C with a decline of 30% or less or an increase (298 cycles).
Did absolute estradiol levels differ between pregnant and non-pregnant groups?
Absolute estradiol differences did not differ significantly between the groups, as the analysis yielded a p-value of 0.878. Proportional change served as the more effective marker.